{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:23:37Z","timestamp":1787847817501,"version":"build-2784847793"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR\u2013TKIs) have become the standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. As resistance to EGFR\u2013TKIs is associated with significantly worse prognosis, there is a critical need to understand the mechanisms underlying resistance and to develop effective subsequent treatment strategies. Immune checkpoint inhibitors (ICIs) show remarkable efficacy in treating solid tumors, including melanoma, esophageal cancer, and NSCLC. The role of immunotherapy in EGFR\u2013TKI-resistant cases has generated varied perspectives among researchers. This article reviews findings on the interplay between EGFR, the tumor microenvironment, and ICIs, as well as recent advances in post-EGFR\u2013TKI resistance treatment strategies. By doing so, this review aims to provide insights for research and clinical management of EGFR\u2013TKI-resistant NSCLC.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1981_25","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:00:18Z","timestamp":1779951618000},"page":"279-289","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer"],"prefix":"10.4103","volume":"22","author":[{"given":"Xinjia","family":"He","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Hospital of Qingdao University and The First Clinical Medical College of Qingdao University, Qingdao City, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou City, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou City, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou City, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260528","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.4103\/jcrt.jcrt_877_22","article-title":"Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors","volume":"19","author":"Dogan","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12890-023-02466-9","article-title":"Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations","volume":"23","author":"Si","year":"2023","journal-title":"BMC Pulm Med"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/fon-2021-0641","article-title":"Soluble PD-L1 as a predictive biomarker in lung cancer: A systematic review and meta-analysis","volume":"18","author":"Cheng","year":"2022","journal-title":"Future Oncol"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/jcrt.jcrt_1031_23","article-title":"Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"20","author":"Yang","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4046\/trd.2019.0026","article-title":"Correlation of PD-L1 expression tested by 22C3 and SP263 in non-small cell lung cancer and its prognostic effect on EGFR mutation-positive lung adenocarcinoma","volume":"83","author":"Kim","year":"2020","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"635007","DOI":"10.3389\/fonc.2021.635007","article-title":"Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies","volume":"11","author":"To","year":"2021","journal-title":"Front Oncol"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"e142843","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.3390\/ijms20153821","article-title":"Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC)","volume":"20","author":"Hsu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/ijc.32191","article-title":"EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies","volume":"145","author":"Jia","year":"2019","journal-title":"Int J Cancer"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","article-title":"Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer","volume":"25","author":"Azuma","year":"2014","journal-title":"Ann Oncol"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00262-021-03030-2","article-title":"EGFR mutation status in non-small cell lung cancer receiving PD-1\/PD-L1 inhibitors and its correlation with PD-L1 expression: A meta-analysis","volume":"71","author":"Yang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"768","DOI":"10.20892\/j.issn.2095-3941.2020.0121","article-title":"Molecular heterogeneity of anti-PD-1\/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer","volume":"17","author":"Jin","year":"2020","journal-title":"Cancer Biol Med"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"131","DOI":"10.31557\/APJCP.2022.23.1.131","article-title":"Correlation between programmed death ligand-1 (PD-L1) expression and driver gene mutations in non-small cell lung carcinoma- adenocarcinoma phenotype","volume":"23","author":"Pandey","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann Oncol"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/1759-7714.13748","article-title":"Immune microenvironment features and efficacy of PD-1\/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions","volume":"12","author":"Chen","year":"2021","journal-title":"Thorac Cancer"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune checkpoint inhibitors in EGFR-mutated NSCLC: Dusk or dawn","volume":"16","author":"Qiao","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.7150\/jca.14713","article-title":"AKT-STAT3 Pathway as a downstream target of EGFR signaling to regulate PD-L1 expression on NSCLC cells","volume":"7","author":"Abdelhamed","year":"2016","journal-title":"J Cancer"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fgene.2016.00197","article-title":"MiR-30a-5p Overexpression may overcome EGFR-inhibitor resistance through regulating PI3K\/AKT signaling pathway in non-small cell lung cancer cell lines","volume":"7","author":"Meng","year":"2016","journal-title":"Front Genet"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-Driven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","article-title":"The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer","volume":"49","author":"Zhang","year":"2016","journal-title":"Int J Oncol"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jcmm.13956","article-title":"Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"100987","DOI":"10.1016\/j.drup.2023.100987","article-title":"Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8\/PD-L1 signaling in NSCLC","volume":"70","author":"Liu","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"114576","DOI":"10.18632\/oncotarget.23051","article-title":"YAP regulates PD-L1 expression in human NSCLC cells","volume":"8","author":"Miao","year":"2017","journal-title":"Oncotarget"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/jcmm.13593","article-title":"Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma","volume":"22","author":"Hsu","year":"2018","journal-title":"J Cell Mol Med"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12935-024-03416-z","article-title":"Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP\/AKT\/BAD-BCL-2 pathway","volume":"24","author":"Liu","year":"2024","journal-title":"Cancer Cell Int"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.3892\/ol.2016.4442","article-title":"Melanoma cell adhesion molecule stimulates yes-associated protein transcription by enhancing CREB activity via c-Jun\/c-Fos in hepatocellular carcinoma cells","volume":"11","author":"Qiao","year":"2016","journal-title":"Oncol Lett"},{"key":"R35-20260528","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","article-title":"Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth","volume":"17","author":"Zanconato","year":"2015","journal-title":"Nat Cell Biol"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"e98642","DOI":"10.15252\/embj.201798642","article-title":"YAP-TEAD signaling promotes basal cell carcinoma development via a c-JUN\/AP1 axis","volume":"37","author":"Maglic","year":"2018","journal-title":"EMBO J"},{"key":"R37-20260528","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.7150\/thno.52435","article-title":"ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"R38-20260528","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/1759-7714.13504","article-title":"Association of CD8 T cell apoptosis and EGFR mutation in non-small lung cancer patients","volume":"11","author":"Zhao","year":"2020","journal-title":"Thorac Cancer"},{"key":"R39-20260528","doi-asserted-by":"crossref","first-page":"eaav3937","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci Immunol"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"e1356145","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-22-3379","article-title":"IL6 Mediates suppression of T- and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R42-20260528","doi-asserted-by":"crossref","first-page":"e009165","DOI":"10.1136\/jitc-2024-009165","article-title":"Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect","volume":"12","author":"Lu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R43-20260528","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11523-024-01072-x","article-title":"Impact of PD-L1 expression on the overall survival of caucasian patients with advanced EGFR-mutant NSCLC treated with frontline osimertinib","volume":"19","author":"Papazyan","year":"2024","journal-title":"Target Oncol"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jtho.2021.07.011","article-title":"Chemotherapy should be combined with checkpoint inhibitors in the treatment of patients with stage IV EGFR-mutant NSCLC whose disease has progressed on all available tyrosine kinase inhibitors","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R45-20260528","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-11-35","article-title":"Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway","volume":"11","author":"Thakur","year":"2013","journal-title":"J Transl Med"},{"key":"R46-20260528","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","article-title":"Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer","volume":"12","author":"Gong","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R47-20260528","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.18632\/oncotarget.24146","article-title":"S100A9 (+) MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: The role of RELB","volume":"9","author":"Feng","year":"2018","journal-title":"Oncotarget"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Front Immunol"},{"key":"R49-20260528","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cllc.2015.02.002","article-title":"Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma","volume":"16","author":"Lin","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"R50-20260528","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2017.01.008","article-title":"Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer","volume":"105","author":"Soo","year":"2017","journal-title":"Lung Cancer"},{"key":"R51-20260528","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.3390\/ijms22126288","article-title":"Anti-PD1\/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations","volume":"22","author":"Dantoing","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R53-20260528","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R54-20260528","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer-biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R55-20260528","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12964-022-00958-5","article-title":"ARID1A deficiency reverses the response to anti-PD (L) 1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production","volume":"20","author":"Sun","year":"2022","journal-title":"Cell Commun Signal"},{"key":"R56-20260528","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1111\/1759-7714.14635","article-title":"Correlations of switch\/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer","volume":"13","author":"Chang","year":"2022","journal-title":"Thorac Cancer"},{"key":"R57-20260528","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cllc.2015.11.006","article-title":"Change in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancer","volume":"17","author":"Han","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R58-20260528","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R59-20260528","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.lungcan.2017.07.022","article-title":"Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer","volume":"111","author":"Hata","year":"2017","journal-title":"Lung Cancer"},{"key":"R60-20260528","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.jtho.2018.09.012","article-title":"Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations","volume":"13","author":"Toki","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R61-20260528","doi-asserted-by":"crossref","first-page":"1758835920930333","DOI":"10.1177\/1758835920930333","article-title":"Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: From bed to bench","volume":"12","author":"Jin","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"R62-20260528","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"R63-20260528","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R64-20260528","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11523-019-00657-1","article-title":"Prior EGFR-TKI treatment in EGFR-mutated NSCLC affects the allele frequency fraction of acquired T790M and the subsequent efficacy of osimertinib","volume":"14","author":"Kuo","year":"2019","journal-title":"Target Oncol"},{"key":"R65-20260528","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"key":"R66-20260528","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"Aphase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R67-20260528","first-page":"CD013257","article-title":"Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer","volume":"4","author":"Ferrara","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R68-20260528","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"R69-20260528","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"R70-20260528","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-A meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R71-20260528","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"R72-20260528","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: Final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"R73-20260528","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): Second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R74-20260528","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-024-03751-7","article-title":"Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): A systematic review and meta-analysis","author":"Zhao","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"R75-20260528","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"key":"R76-20260528","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R77-20260528","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jtho.2018.11.028","article-title":"Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R78-20260528","first-page":"1200","article-title":"Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice","volume":"9","author":"Kim","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R79-20260528","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/leu.2011.24","article-title":"Immunomodulatory effects of anti-angiogenic drugs","volume":"25","author":"Heine","year":"2011","journal-title":"Leukemia"},{"key":"R80-20260528","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.biopha.2017.01.051","article-title":"The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment","volume":"88","author":"Hu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"R81-20260528","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R82-20260528","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2020.10.004","article-title":"Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R83-20260528","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"R84-20260528","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with egfr mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R85-20260528","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: First approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"R86-20260528","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: A randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"R87-20260528","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","article-title":"Aphase 1b study of ivonescimab, a programmed cell death protein-1 and vascular endothelial growth factor bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy-naive NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1981_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:39:18Z","timestamp":1787845158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1981_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1981_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-09-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}